News and Features
AIDSinfo Updates Consumer Fact Sheets on HIV Treatment
The updated AIDSinfo consumer fact sheets provide important information about HIV treatment. Each fact sheet includes a summary of key points and links to additional information and resources.
View the updated fact sheets:
- HIV Treatment: The Basics
- Just Diagnosed: Next Steps After Testing Positive for HIV
- When to Start Antiretroviral Therapy
- What to Start: Choosing an HIV Regimen
- FDA-Approved HIV Medicines
- Drug Resistance
- HIV Medication Adherence
- Following an HIV Regimen: Steps to Take Before and After Starting HIV Medicines
- HIV and Immunizations
- What is a Drug Interaction?
Scientific/Clinical Member Nominations Are Now Being Accepted for the Department of Health and Human Services (HHS) Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV
The HHS Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (or the Panel) is accepting nominations for new scientific/clinical members with expertise in HIV medicine. The Panel is seeking candidates with expertise in:
- pharmacology of antiretrovirals in infants, children, and adolescents
- clinical use of antiretrovirals in infants and children
- care of adolescents and young adults with perinatally acquired HIV
Panel members critically evaluate new information and prepare guideline revisions. The candidates should be recognized experts in their areas of interest. The successful candidates will serve a 3-year term beginning April 2018, with potential for reappointment for an additional term.
The Panel is a Working Group of the Office of AIDS Research Advisory Council of the National Institutes of Health. The Panel is composed of approximately 30 members who are clinicians, researchers, academicians, HHS representatives, and community representatives with expertise in HIV management in the United States. The Panel meets monthly via teleconferencing to review and critically evaluate emerging scientific data relating to antiretroviral therapy in children and to revise the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection.
Panel members are not financially compensated for their time commitment.
The nomination should include a curriculum vitae and a letter of interest or a letter of nomination with specific reference to how the nominee would contribute to the work of the Panel. Self-nomination is welcome. All supporting documents should be submitted to Angie Landenburger, AIDSinfo Guidelines Coordinator, at firstname.lastname@example.org, no later than February 23, 2018.
FDA Approves Biktarvy (a Fixed-Dose Combination Tablet) to Treat HIV Infection
On February 7, 2018, the Food and Drug Administration (FDA) approved Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide), a three-drug, fixed-dose combination tablet indicated as a complete regimen for the treatment of HIV-1 infection in adults who have no antiretroviral treatment history or to replace the current antiretroviral regimen in people who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 3 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Biktarvy.
The Biktarvy label is available on the FDA website.